Seelos Therapeutics Inc (SEEL)

[eicoman]

Here's the most important slide from the new corp presentation:

Additional Clinical Efficacy Analysis:
• Assessment of clinical meaningfulness (MCID) demonstrated clinically
important differences across all dosing cohorts
• Anchor based analysis results indicated that each of the 5 potential
anchors met the meaningful change threshold

Updated Safety:
• We believe safety deficiencies from CRL have been fully addressed
• Clinical safety profile from phase 3 studies has not changed with
greater than 1 million uses around the world
• The majority of AEs have been mild to moderate, local to the site of
administration, transient in nature with event durations of less than
two hours

Updated CMC/Module 3:
• All the CMC deficiencies from the CRL have been addressed
• Results from successful Human Factors Test were included in
resubmission
• Manufacturing process and manufacturing sites were updated in the
resubmission